Hypofractionated Radiotherapy for Lung Cancer

The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00214123

Enrollment

Registered

2005-09-21

Start date

2004-06-30

Completion date

2012-12-31

Last updated

2019-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Interventions

RADIATIONradiation therapy (radiotherapy)

Bin assignment based on tumor volume

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Exclusion criteria

* Prior bleomycin or gemcitabine chemotherapy * Prior thoracic radiotherapy

Design outcomes

Primary

Measure	Time frame
Grade 3 pneumonitis lasting greater than 2 weeks	90 days post radiotherapy (XRT)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026